The PEACE (Posthumous Evaluation of Advanced Cancer Environment) Study

• Sponsor: University College, London (Other)
• Overall Status: Recruiting
• CT.gov ID: NCT03004755
• Collaborator: Cancer Research UK (Other)
• Enrollment: 500
• Locations: 9
• Duration (Months): 116
• Patients Per Site: 55.6
• Patients Per Site Per Month: 0.5

Study Details

Study Description

Brief Summary

Historically, cancer research has been limited by sample acquisition in late stage disease, often restricted to single sites of disease with limited parallel clinical data collection in terms of prior therapy exposure. The PEACE study is intended to facilitate tissue donation from multiple tumour sites in the post-mortem setting and enable future research using samples collected at post-mortem within different disciplines related to cancer research.

Condition or Disease	Intervention/Treatment	Phase
Solid Tumor, Adult; Cancer	Other: Tissue Harvest

Study Design

• Study Type: Observational
• Anticipated Enrollment: 500 participants
• Observational Model: Cohort
• Time Perspective: Prospective
• Official Title: The PEACE (Posthumous Evaluation of Advanced Cancer Environment) Study
• Study Start Date: Mar 1, 2014
• Anticipated Primary Completion Date: Nov 1, 2023
• Anticipated Study Completion Date: Nov 1, 2023

Outcome Measures

Primary Outcome Measures

1. Perform 500 post mortems [5 years]

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• Age 18 years or older

• Confirmed diagnosis of any form of solid malignancy with metastatic disease (where the site of origin is known or unknown), with the exception of primary brain tumour in which there may not be evidence of metastatic disease

• Oral and written informed consent from patient to enter the study and to undergo tumour harvesting after death or informed consent from a person in a qualifying relationship after the patient has died.

Exclusion Criteria:

• Medical or psychiatric condition that would preclude informed consent

• History of intravenous drug abuse within the last 5 years

• History of known high-risk infections (e.g. HIV/AIDS-positive, hepatitis B/C, tuberculosis and Creutzfeldt-Jacob disease).

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Heart of England NHS Foundation Trust	Birmingham		United Kingdom
2	Cambridge University NHS Trust	Cambridge		United Kingdom
3	Greater Glasgow Health Board	Glasgow		United Kingdom
4	University Hospitals of Leicester NHS Trust	Leicester		United Kingdom
5	Guy's and St Thomas NHS Foundation Trust	London		United Kingdom
6	The Royal Marsden NHS Foundation Trust	London		United Kingdom
7	University College London Hospitals NHS Foundation Trust	London		United Kingdom
8	The Christie NHS Foundation Trust	Manchester		United Kingdom
9	Oxford University Hospitals NHS Trust	Oxford		United Kingdom

Sponsors and Collaborators

• University College, London
• Cancer Research UK

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: University College, London
• ClinicalTrials.gov Identifier: NCT03004755
• Other Study ID Numbers: UCL/13/0165
• First Posted: Dec 29, 2016
• Last Update Posted: Feb 23, 2022
• Last Verified: Feb 1, 2022

Study Results

No Results Posted as of Feb 23, 2022